Amfetamine/guanfacine - Genco Sciences

Drug Profile

Amfetamine/guanfacine - Genco Sciences

Latest Information Update: 21 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genco Sciences
  • Class Acetamides; Amphetamines; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Alpha 2 adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gilles de la Tourette's syndrome

Most Recent Events

  • 17 Mar 2016 Guanfacine/amphetamine - Genco Sciences receives Orphan Drug status for Gilles de la Tourette's syndrome in USA
  • 25 Apr 2011 Genco files for patent protection with USPTO for formulations to reduce drug side effects, including guanfacine/amfetamine in USA
  • 25 Apr 2011 Preclinical trials in Gilles de la Tourette's syndrome (In children, In infants, In neonates, In adolescents) in USA (unspecified route) before October 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top